Search results
Results from the WOW.Com Content Network
The US Food and Drug Administration FDA reports [10] that some drugs in this class (isoxazolines), including afoxolaner, can have adverse neurologic effects on some dogs, such as muscle tremors, ataxia, and convulsions. Extralabel use of afoxolaner in a pet pig has been described without any adverse effects. [11]
Oral administration of a liquid. In pharmacology and toxicology, a route of administration is the way by which a drug, fluid, poison, or other substance is taken into the body. [1] Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration ...
This is a list of abbreviations used in medical prescriptions, including hospital orders (the patient-directed part of which is referred to as sig codes).This list does not include abbreviations for pharmaceuticals or drug name suffixes such as CD, CR, ER, XT (See Time release technology § List of abbreviations for those).
The US Food and Drug Administration (FDA) approved it for flea treatment in dogs in May 2014, [17] and approved the combination fluralaner/moxidectin (Bravecto Plus) as a topical treatment for cats in November 2019.
5-MAPB was originally banned in the UK in June 2013 under a Temporary class drug order. [19] On March 5, 2014, the UK Home Office announced that 5-MAPB would be made a class B drug on 10 June 2014 alongside every other benzofuran entactogen and many structurally related drugs.
Meptazinol, sold under the brand name Meptid, is an opioid analgesic developed by Wyeth in the 1970s. [1] Indications for use in moderate to severe pain, most commonly used to treat pain in obstetrics ().
Oxiracetam (developmental code name ISF 2522) is a nootropic drug of the racetam family and a very mild stimulant. [1] [2] Several studies suggest that the substance is safe even when high doses are consumed for a long period of time. [3] [4] [5] However, the mechanism of action of the racetam drug family is still a
In 2021, the Food and Drug Administration (FDA) issued the following warning [13] in regard to recreational use of propylhexedrine products in manners inconsistent with their labeling: ...[T]he abuse and misuse of the over-the-counter (OTC) nasal decongestant propylhexedrine can lead to serious harm such as heart and mental health problems.